Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).
作者信息
Furst D E, Breedveld F C, Kalden J R, Smolen J S, Antoni C E, Bijlsma J W J, Burmester G R, Cronstein B, Keystone E C, Kavanaugh A, Klareskog L
机构信息
University of California, Los Angeles, CA, USA.
出版信息
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii2-7. doi: 10.1136/ard.61.suppl_2.ii2.
Abstract
摘要
相似文献
1
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii2-7. doi: 10.1136/ard.61.suppl_2.ii2.
2
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii2-25. doi: 10.1136/ard.2008.100834.
3
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii2-22. doi: 10.1136/ard.2007.081430.
4
The use of biological therapy in refractory rheumatic diseases other than rheumatoid arthritis: experience at a tertiary care center in Lebanon.
Rheumatol Int. 2009 Aug;29(10):1255-7. doi: 10.1007/s00296-008-0816-0. Epub 2008 Dec 4.
5
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv2-14. doi: 10.1136/ard.2005.044941.
6
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001).
Ann Rheum Dis. 2001 Nov;60 Suppl 3(Suppl 3):iii2-5. doi: 10.1136/ard.60.90003.iii2.
7
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
Ann Rheum Dis. 2006 Nov;65 Suppl 3(Suppl 3):iii2-15. doi: 10.1136/ard.2006.061937.
8
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.
Ann Rheum Dis. 2012 Apr;71 Suppl 2:i2-45. doi: 10.1136/annrheumdis-2011-201036.
9
Future use of biologic agents alone and in combination for the treatment of rheumatoid arthritis.
Z Rheumatol. 1998 Feb;57(1):41-5. doi: 10.1007/s003930050058.
10
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000).
Ann Rheum Dis. 2000 Nov;59 Suppl 1(Suppl 1):i1-2. doi: 10.1136/ard.59.suppl_1.i1.
引用本文的文献
1
The Derivative of Hook F-Kunxian Capsule, Attenuated Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Evid Based Complement Alternat Med. 2020 Aug 12;2020:4178140. doi: 10.1155/2020/4178140. eCollection 2020.
2
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study.
Clin Rheumatol. 2017 Feb;36(2):251-260. doi: 10.1007/s10067-016-3444-1. Epub 2016 Oct 25.
3
Ultrasound Detection of Salmonella Septic Arthritis in a Rheumatoid Arthritis Patient on Anti-TNF Treatment.
J Investig Med High Impact Case Rep. 2014 Apr 17;2(2):2324709614532799. doi: 10.1177/2324709614532799. eCollection 2014 Apr-Jun.
4
A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.
Int J Rheum Dis. 2016 Nov;19(11):1157-1168. doi: 10.1111/1756-185X.12711. Epub 2015 Jul 14.
5
Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial.
Ann Rheum Dis. 2008 Sep;67(9):1267-70. doi: 10.1136/ard.2007.081331. Epub 2008 Jan 18.
6
Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography.
Clin Rheumatol. 2008 Apr;27(4):491-6. doi: 10.1007/s10067-007-0738-3. Epub 2007 Oct 19.
7
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
Ann Rheum Dis. 2007 Nov;66 Suppl 3(Suppl 3):iii2-22. doi: 10.1136/ard.2007.081430.
8
Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica.
Drugs Aging. 2006;23(5):391-402. doi: 10.2165/00002512-200623050-00003.
9
[Modern antirheumatic pharmacotherapy. Low molecular weight substances vs. biologicals].
Internist (Berl). 2005 Dec;46(12):1399-404. doi: 10.1007/s00108-005-1501-y.
10
A disease activity score for polymyalgia rheumatica.
Ann Rheum Dis. 2004 Oct;63(10):1279-83. doi: 10.1136/ard.2003.011379.
本文引用的文献
1
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.
Lancet. 2002 Apr 6;359(9313):1187-93. doi: 10.1016/s0140-6736(02)08215-6.
2
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Arthritis Rheum. 2002 Mar;46(3):614-24. doi: 10.1002/art.10141.
3
Targeting interleukin-1 in the treatment of rheumatoid arthritis.
Arthritis Rheum. 2002 Mar;46(3):574-8. doi: 10.1002/art.10168.
4
Remission of Behçet's syndrome with TNFalpha blocking treatment.
Ann Rheum Dis. 2002 Mar;61(3):283-4. doi: 10.1136/ard.61.3.283-a.
5
Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.
Arthritis Rheum. 2001 Dec;44(12):2862-9. doi: 10.1002/1529-0131(200112)44:12<2862::aid-art474>3.0.co;2-w.
6
Infliximab in patients with primary Sjögren's syndrome: a pilot study.
Arthritis Rheum. 2001 Oct;44(10):2371-5. doi: 10.1002/1529-0131(200110)44:10<2371::aid-art401>3.0.co;2-w.
7
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
N Engl J Med. 2001 Oct 11;345(15):1098-104. doi: 10.1056/NEJMoa011110.
8
Effect of infliximab on sight-threatening panuveitis in Behçet's disease.
Lancet. 2001 Jul 28;358(9278):295-6. doi: 10.1016/s0140-6736(01)05497-6.
9
Evaluation and documentation of rheumatoid arthritis disease status in the clinic: which variables best predict change in therapy.
J Rheumatol. 2001 Jul;28(7):1712-7.
10
Osteopontin: an intrinsic inhibitor of inflammation in cartilage.
Arthritis Rheum. 2001 Mar;44(3):578-84. doi: 10.1002/1529-0131(200103)44:3<578::AID-ANR106>3.0.CO;2-7.
Zotero 插件